Propel Bio Management, LLC
Clone Performance
Feb 2024–Sep 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. Returns use comparable raw closes and exclude dividends. Returns are unavailable when a held security or benchmark crosses a captured split without a certified price basis; the requested window is not shortened to hide it. It tracks 100% of reported value on average across 11 quarters. Past performance does not predict future results.
Portfolio Concentration
29 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 83.8% | $160,205,526 |
| Energy | 16.2% | $30,880,177 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| MIST | Milestone Pharmaceuticals Inc. | +3,311,269 | 7,429,590 | $9,955,650 | |
| PALI | Palisade Bio, Inc. | +1,467,388 | 2,582,388 | $5,397,190 | |
| AQST | Aquestive Therapeutics, Inc. | +731,409 | 1,442,397 | $6,000,371 | |
| IVA | Inventiva S.A. | +556,534 | 1,281,212 | $4,842,981 | |
| ARTV | Artiva Biotherapeutics, Inc. | +550,067 | 696,436 | $6,755,429 | |
| ACHV | Achieve Life Sciences, Inc. | +247,593 | 4,034,018 | $26,342,137 | |
| KYTX | Kyverna Therapeutics, Inc. | +238,777 | 883,198 | $7,869,294 | |
| PHAT | Phathom Pharmaceuticals, Inc. | +209,086 | 1,050,358 | $11,396,384 | |
| OVID | Ovid Therapeutics Inc. | +194,081 | 1,115,538 | $3,000,797 | |
| SABS | SAB Biotherapeutics, Inc. | +63,788 | 1,076,578 | $4,198,654 | |
| UPB | Upstream Bio, Inc. | +8,610 | 350,389 | $2,424,691 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| IMUX | Immunic, Inc. | −2,019,757 | 325,022 | $4,995,588 | |
| ABEO | Abeona Therapeutics Inc. | −346,829 | 983,070 | $6,075,372 | |
| CMPS | COMPASS Pathways plc | −168,963 | 573,086 | $8,109,166 | |
| FDMT | 4D Molecular Therapeutics, Inc. | −127,766 | 252,654 | $3,360,298 | |
| DCTH | Delcath Systems, Inc. | −108,238 | 871,460 | $10,971,681 | |
| ZVRA | Zevra Therapeutics, Inc. | −28,874 | 253,544 | $3,635,820 | |
| CLDX | Celldex Therapeutics, Inc. | −27,669 | 103,695 | $3,858,490 | |
| OCUL | Ocular Therapeutix, Inc | −24,409 | 357,966 | $3,515,226 | |
| EYPT | EyePoint, Inc. | −24,080 | 191,745 | $2,741,953 | |
| CRVS | Corvus Pharmaceuticals, Inc. | −15,411 | 70,380 | $1,051,477 | |
| CORT | Corcept Therapeutics Inc | −11,329 | 136,499 | $11,868,588 | |
| No positions match the current search. | |||||
Sold Out
Positions the filer fully exited| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| VOR | Vor Biopharma Inc. | 314,543 | $5,611,447 | |
| VRDN | Viridian Therapeutics, Inc.\DE | 210,163 | $4,110,788 | |
| OCS | Oculis Holding AG | 122,223 | $3,249,909 | |
| TRVI | Trevi Therapeutics, Inc. | 223,802 | $2,669,957 | |
| CHRS | Coherus Oncology, Inc. | 1,420,550 | $2,400,729 | |
| QURE | uniQure N.V. | 104,772 | $1,713,022 | |
| KLRS | Kalaris Therapeutics, Inc. | 295,771 | $1,706,598 | |
| NUVB | Nuvation Bio Inc. | 329,296 | $1,412,679 | |
| EVMN | Evommune, Inc. | 55,664 | $1,279,715 | |
| ALDX | Aldeyra Therapeutics, Inc. | 730,606 | $1,234,724 | |
| CNTB | Connect Biopharma Holdings Ltd | 209,493 | $548,871 | |
| MSLE | Satellos Bioscience Inc. | 10,145 | $57,116 | |
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| PAGP |
Plains Gp Holdings LP
Energy
|
Held | 1,272,360 | $30,880,177 | 16.16% | |
| ACHV |
Achieve Life Sciences, Inc.
Healthcare
|
Added | 4,034,018 | $26,342,137 | 13.79% | |
| CORT |
Corcept Therapeutics Inc
Healthcare
|
Reduced | 136,499 | $11,868,588 | 6.21% | |
| PHAT |
Phathom Pharmaceuticals, Inc.
Healthcare
|
Added | 1,050,358 | $11,396,384 | 5.96% | |
| DCTH |
Delcath Systems, Inc.
Healthcare
|
Reduced | 871,460 | $10,971,681 | 5.74% | |
| MIST |
Milestone Pharmaceuticals Inc.
Healthcare
|
Added | 7,429,590 | $9,955,650 | 5.21% | |
| CMPS |
COMPASS Pathways plc
Healthcare
|
Reduced | 573,086 | $8,109,166 | 4.24% | |
| KYTX |
Kyverna Therapeutics, Inc.
Healthcare
|
Added | 883,198 | $7,869,294 | 4.12% | |
| ARTV |
Artiva Biotherapeutics, Inc.
Healthcare
|
Added | 696,436 | $6,755,429 | 3.54% | |
| ABEO |
Abeona Therapeutics Inc.
Healthcare
|
Reduced | 983,070 | $6,075,372 | 3.18% | |
| AQST |
Aquestive Therapeutics, Inc.
Healthcare
|
Added | 1,442,397 | $6,000,371 | 3.14% | |
| PALI |
Palisade Bio, Inc.
Healthcare
|
Added | 2,582,388 | $5,397,190 | 2.82% | |
| IMUX |
Immunic, Inc.
Healthcare
|
Reduced | 325,022 | $4,995,588 | 2.61% | |
| IVA |
Inventiva S.A.
Healthcare
|
Added | 1,281,212 | $4,842,981 | 2.53% | |
| SABS |
SAB Biotherapeutics, Inc.
Healthcare
|
Added | 1,076,578 | $4,198,654 | 2.20% | |
| OBIO |
Orchestra BioMed Holdings, Inc.
Healthcare
|
Held | 896,701 | $3,869,264 | 2.02% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
Reduced | 103,695 | $3,858,490 | 2.02% | |
| ZVRA |
Zevra Therapeutics, Inc.
Healthcare
|
Reduced | 253,544 | $3,635,820 | 1.90% | |
| OCUL |
Ocular Therapeutix, Inc
Healthcare
|
Reduced | 357,966 | $3,515,226 | 1.84% | |
| FDMT |
4D Molecular Therapeutics, Inc.
Healthcare
|
Reduced | 252,654 | $3,360,298 | 1.76% | |
| OVID |
Ovid Therapeutics Inc.
Healthcare
|
Added | 1,115,538 | $3,000,797 | 1.57% | |
| EYPT |
EyePoint, Inc.
Healthcare
|
Reduced | 191,745 | $2,741,953 | 1.43% | |
| UPB |
Upstream Bio, Inc.
Healthcare
|
Added | 350,389 | $2,424,691 | 1.27% | |
| SCYX |
Scynexis Inc
Healthcare
|
NEW | 543,478 | $2,211,955 | 1.16% | |
| SLN |
Silence Therapeutics plc
Healthcare
|
NEW | 191,733 | $2,105,228 | 1.10% | |
| LONA |
LeonaBio, Inc.
Healthcare
|
Held | 149,279 | $1,371,874 | 0.72% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
Held | 43,798 | $1,306,932 | 0.68% | |
| CRVS |
Corvus Pharmaceuticals, Inc.
Healthcare
|
Reduced | 70,380 | $1,051,477 | 0.55% | |
| SGMT |
Sagimet Biosciences Inc.
Healthcare
|
NEW | 125,878 | $973,036 | 0.51% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.